Subcutaneous bioavailability of taspoglutide at three different injection sites in healthy overweight/obese subjects: a randomised, open-label, 3-way crossover phase I study

Trial Profile

Subcutaneous bioavailability of taspoglutide at three different injection sites in healthy overweight/obese subjects: a randomised, open-label, 3-way crossover phase I study

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Taspoglutide (Primary)
  • Indications Obesity; Overweight; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 05 Nov 2015 New trial record
    • 26 Sep 2015 Results published in Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top